External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer: Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 3, 2009, Pages 759-765

  Ogawa, Kazuhiko ^a   Nakamura, Katsumasa ^b   Sasaki, Tomonari ^c   Onishi, Hiroshi ^d   Koizumi, Masahiko ^e   Shioyama, Yoshiyuki ^f   Araya, Masayuki ^d   Mukumoto, Nobutaka ^e   Mitsumori, Michihide ^g   Teshima, Teruki ^e  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g KYOTO UNIVERSITY   (Japan)

Author keywords

Hormone refractory; nPSA12; Prognostic factor; Prostate cancer; Radiotherapy

Indexed keywords

CLINICAL FAILURE; CLINICAL OUTCOME; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; LOCAL CONTROL; LYMPH NODE METASTASIS; MULTI VARIATE ANALYSIS; NPSA12; OVERALL SURVIVAL; PRE-TREATMENT; PROGNOSTIC FACTOR; PROGNOSTIC FACTORS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; SIGNIFICANT IMPACTS; TOTAL RADIATION DOSE; UNIVARIATE ANALYSIS; UP PERIOD;

ANTIGENS; DECISION MAKING; INFRARED SPECTROMETERS; MULTIVARIANT ANALYSIS; PATHOLOGY; PEELING; REFRACTORY MATERIALS;

RADIOTHERAPY;

ANTIANDROGEN; ESTRAMUSTINE; ESTROGEN; FLUOROURACIL; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; RADIATION RESPONSE; TREATMENT FAILURE;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 67049107507     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.08.067     Document Type: Article

References (35)

1. Egawa S., Go M., Kuwano S., et al. Long-term impact of conservative management on localized prostate cancer. A twenty-year experience in Japan. Urology 42 (1993) 520-526
2. Kotake T., Usami M., Akaza H., et al. Goserlin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: A multicenter, randomized, controlled trial in Japan. Zoladex Study Group. Jpn J Clin Oncol 29 (1999) 562-570
3. Kolvenbag G.J., Iversen P., and Newling D.W. Antiandrogen monotherapy: A new form of treatment for patients with prostate cancer. Urology 58 2 Suppl. 1 (2001) 16-23
4. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164 (2000) 1579-1582
5. DeLa Taille A., Vacherot F., Salomon L., et al. Hormone-refractory prostate cancer: A multi-step and multi-event process. Prostate Cancer Prostate Dis 4 (2001) 204-212
6. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory prostate cancer. J Clin Oncol 21 (2003) 1232-1237
7. Kraus P.A., Lytton B., Weiss R.M., et al. Radiation therapy fro local palliative treatment of prostate cancer. J Urol 108 (1972) 612-614
8. Furuya Y., Akakura K., Akimoto S., et al. Radiotherapy for local progression in patients with hormone-refractory prostate cancer. Int J Urol 6 (1999) 187-191
9. Lankford S.P., Pollack A., and Zagars G.K. Radiotheray for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys 33 (1999) 907-912
10. Alcabtare P., Hanlon A., Buyyounouski M.K., et al. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109 (2007) 41-47
11. Ray M.E., Levy L.B., Horwitz E.M., et al. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 68 (2006) 1257-1262
12. Zeitman A.L., Tibbs M.K., Dallow K.C., et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 40 (1996) 159-162
13. Lee W.R., Hanlon A.L., and Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival. J Urol 156 (1996) 450-453
14. Crook J.M., Bahadur Y.A., Bociek R.G., et al. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcomes as assessed by systematic biopsy and serum prostate specific antigen. Cancer 79 (1997) 328-336
15. Ray M.E., Thames H.D., Levy L.B., et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Int J Radiat Oncol Biol Phys 64 (2006) 1140-1150
16. Hanlon A.L., Diratzouian H., and Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 297-303
17. Pollack A., Hanlon A.L., Movsas B., et al. Biochemical failure as determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 19-23
18. Teshima T. Patterns of Care Study in Japan. Jpn J Clin Oncol 35 (2005) 497-506
19. Nakamura K., Teshima T., Takahashi Y., et al. Radical radiotherapy for prostate cancer in Japan: A Patterns of Care Study report. Jpn J Clin Oncol 33 (2003) 122-126
20. Nakamura K., Teshima T., Takahashi Y., et al. Radiotherapy for localized hormone-refractory prostate cancer in Japan. Anticancer Res 24 (2004) 3141-3145
21. Ogawa K., Nakamura K., Onishi H., et al. Radical external beam radiotherapy for clinically localized prostate cancer in Japan: Changing trends in the patterns of care process survey between 1996-1998 and 1999-2001. Anticancer Res 25 (2005) 3507-3511
22. Ogawa K., Nakamura K., Onishi H., et al. Radical external beam radiotherapy for prostate cancer in Japan: Results of the 1999-2001 patterns of care process survey. Jpn J Clin Oncol 36 (2006) 40-45
23. Ogawa K., Nakamura K., Onishi H., et al. Radical external beam radiotherapy for clinically localized prostate cancer in Japan: Differences in the patterns of care between Japan and the United States. Anticancer Res 26 (2006) 575-580
24. Ogawa K., Nakamura K., Onishi H., et al. Influence of age on the pattern and outcome of external beam radiotherapy for clinically localized prostate cancer. Anticancer Res 26 (2006) 1319-1325
25. Hanks G.E., Coia L.R., and Curry J. Patterns of care studies: Past, present and future. Semin Radiat Oncol 7 (1997) 97-100
26. Owen J.B., Sedransk J., and Pajak T.F. National averages for process and outcome in radiation oncology: Methodology of the Patterns of Care Study. Semin Radiat Oncol 7 (1997) 101-107
27. SAS Institute. SAS procedure reference, version 6. 1st ed. (1995), SAS Institute in Japan, Tokyo
28. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
29. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
30. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
31. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
32. Akimoto T., Kitamoto Y., Saito J.I., et al. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: Impact of pretreatment PSA value on radiotherapeutic outcomes. Int J Radiat Oncol Biol Phys 59 (2004) 372-379
33. Sanguineti G., Marcenaro M., Franzone P., et al. Is there a "curative" role of radiotherapy for clinically localized hormone refractory prostate cancer?. Am J Clin Oncol 27 (2004) 264-268
34. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1511
35. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520